Patents by Inventor Eric W. Olle

Eric W. Olle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS
    Publication number: 20150218273
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Application
    Filed: April 17, 2015
    Publication date: August 6, 2015
    Applicant: BENOVUS BIO, INC.
    Inventor: Eric W. Olle
  • Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
    Patent number: 9012155
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: April 21, 2015
    Assignee: Benovus Bio, Inc.
    Inventor: Eric W. Olle
  • ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS
    Publication number: 20130336894
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 19, 2013
    Inventor: Eric W. Olle
  • Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
    Patent number: 8491893
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: July 23, 2013
    Assignee: Quantum Immunologics, Inc.
    Inventor: Eric W. Olle
  • Oncofetal Antigen/Immature Laminin Receptor Peptides for the Sensitization of Dendritic Cells for Cancer Therapy
    Publication number: 20100316574
    Abstract: The present invention relates to methods of making peptides or a mixture of peptides that can be used to pulse dendritic cells against the oncofetal antigen/immature laminin receptor protein (OFA/iLRP). More specifically, dendritic cells can be derived from a range of different sources that can direct the immune system to attack specific antigens. Once sensitized, either ex vivo, in vivo or in vitro, the dendritic cells will aid an individual's own immune system to protect against or treat all types of OFA/iLRP-related cancer. The peptides may also be used for detection, diagnosis and monitoring, and treatment of a OFA/iLRP-related cancer.
    Type: Application
    Filed: March 26, 2010
    Publication date: December 16, 2010
    Applicant: Quantum Immunologics, Inc.
    Inventor: Eric W. Olle
  • ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS
    Publication number: 20100247536
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Application
    Filed: March 26, 2010
    Publication date: September 30, 2010
    Applicant: Quantum Immunologics, Inc.
    Inventor: Eric W. Olle